Latest Breaking News On - Howardw robin - Page 3 : comparemela.com

Nektar Therapeutics Reports First Quarter 2023 Financial Results

Nektar Therapeutics Reports First Quarter 2023 Financial Results

/PRNewswire/ Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2023. Cash and investments in.

Nektar Therapeutics (NKTR) to Regain Full Rights to Rezpegaldesleukin

Nektar Regains Full Rights Of REZPEG From Eli Lilly, Plans To Initiate Phase 2b Study

(RTTNews) - Nektar Therapeutics (NKTR) Thursday announced that it will be regaining the full rights to REZPEG from Eli Lilly and Company. The comp.

Fresh layoffs at Nektar Therapeutics as it drops lupus program after phase 2 disappointment

Following a recent phase 2 failure, the San Francisco-based biotech company Nektar Therapeutics has slashed its workforce and axed the development of the protein drug rezpegaldesleukin (Rezpeg) for the treatment of the autoimmune disease systemic lupus erythematosus (SLE).